Albert Bourla assures that his company “is performing phenomenally” in the portfolio of anti-cancer drugs, which they acquired from a biotechnology company they bought a year ago.
The executive director of Pfizer, Albert Bourlahe assured this Thursday, in an interview with the program The Claman Countdownthat the field of oncology became the new objective of the American pharmaceutical company now that the coronavirus pandemic has come to an end.
“Oncology is our new covid“, he indicated Bourla about the branch of medicine specialized in the diagnosis and treatment of cancer in which they are entering. He also said that the company feels “very proud” of its actions to stop the coronavirus, although he stressed that that stage “is now behind us.”
“We want to do it again, and I think oncology is our best opportunity to do it, but of course with many other therapeutic areas,” he added. At one point in the interview, the program host asked the CEO of Pfizer what could be the “blockbuster drugs” related to oncology, to which Bourla responded that they will be those that will have “a significant impact on cancer patients.”
Focus on anti-cancer drugs
At the same time, Bourla He detailed that the company “is having a phenomenal portfolio performance” of drugs that use the patented technology for the treatment of cancer known as ‘antibody-drug conjugate’ (ADC), which was acquired by Pfizer when purchasing the biotechnology company Seagen.
One of these medications is Padcev, which is mainly used to treat bladder cancer. In accordance with Bourlasales of Padcev They recorded a growth of 164% now that the catalog of oncology drugs belongs to Pfizer. “That shows how well this money was invested,” he noted. According to the drug.com portal, the cost of a 20 milligram dose of Padcev around $2,900.
Finally, Bourla He commented that he feels “very happy” since his medications are “helping people,” adding that, after reviewing the sales process for drugs with ADC technology, he anticipates that Pfizer will move “towards overall cancer survival.”
In March 2023, Pfizer announced that it had reached a definitive merger agreement to acquire Seagen for $43 billion, and in December of that year, the pharmaceutical company’s purchase of the biotechnology company was finalized.
Last February, Pfizer’s director of oncology, Chris Boshoffreported that the company is expected to have at least eight blockbuster cancer drugs by 2030. The site Fierce Pharma He detailed that Pfizer will focus on four main types of cancer: breast, genitourinary, blood and thoracic, for which it already has commercial products.
